Table 1.
Baseline characteristics of study subjects (n = 92)
| Variable | Value |
|---|---|
| Age (yr) | 52.5 (45–61) |
| Sex | |
| Male | 51 (55.4) |
| Female | 41 (44.6) |
| Primary tumour site | |
| Right colon | 21 (22.8) |
| Left colon | 33 (35.9) |
| Rectum | 38 (41.3) |
| Histologic subtype | |
| Well/moderately differentiate | 81 (88.0) |
| Poorly differentiated | 11 (12.0) |
| Signet-ring cell cancer | 5 (5.4) |
| Clinical T stage | |
| T2 | 9 (9.8) |
| T3 | 67 (72.8) |
| T4 | 16 (17.4) |
| Clinical N stage | |
| N0 | 42 (45.7) |
| N1 | 42 (45.7) |
| N2 | 8 (8.7) |
| Pelvic nodes in rectal cancer (n = 38) | 9 (23.7) |
| Extra-hepatic metastasis | |
| None | 79 (85.9) |
| Lung | 5 (5.4) |
| Retroperitoneal nodes | 3 (3.3) |
| Peritoneum | 5 (5.4) |
| Carcinoembryonic antigen (ng/mL) | 18.7 (4.6–56) |
| Performance status (Eastern Cooperative Oncology Group) | |
| 0 | 13 (14.1) |
| 1 | 76 (82.6) |
| 2 | 3 (3.3) |
| Comorbidity (ASA scale) | |
| 1 | 50 (54.3) |
| 2 | 39 (42.4) |
| 3 | 3 (3.3) |
| Body mass index (kg/m2) | 22.9 (21–25.7) |
| Hemoglobin (g/dL) | 11.2 (10–12.8) |
| Albumin (g/dL) | 3.8 (3.6–4.2) |
| BRAF status (n = 13) | |
| Wild | 12 (92.3) |
| Mutant | 1 (7.7) |
| KRAS (n = 45) | |
| Wild | 32 (71.1) |
| Mutant | 13 (28.9) |
| Number of liver metastasis | 2 (1–8) |
| Distribution of liver metastasis | |
| Unilobar | 63 (68.5) |
| Bilobar | 29 (31.5) |
| Size of largest metastasis (cm) | 3 (1–15) |
| Portal lymphadenopathy | 6 (6.5) |
| Fong’s clinical risk score | |
| 0 | 0 |
| 1 | 20 (21.7) |
| 2 | 43 (46.7) |
| 3 | 27 (29.3) |
| 4 | 1 (1.1) |
| 5 | 1 (1.1) |
| Preoperative chemotherapy | 63 (68.5) |
| Chemotherapy regimens (n = 63) | |
| FOLFOX/CapeOx | 50 (79.4) |
| Single agent Capecitabine | 5 (7.9) |
| FOLFIRINOX | 4 (6.3) |
| FOLFIRI | 4 (6.3) |
| Number of chemotherapy cycles (n = 63) | 4 (2–13) |
| Targeted therapy (n = 63) | 7 (11.1) |
| Preoperative radiation in rectal cancers (n = 38) | 32 (84.2) |
Values are presented as median (interquartile range) or number (%).
FOLFOX, 5-fluorouracil and oxaliplatin; CapeOX, capecitabine and oxaliplatin; FOLFIRINOX, 5-flurouracil, Irinotecan, oxaliplatin; FOLFIRI, 5-flurouracil, irinotecan.